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Sex difference in cardiovascular risk is offset by presence of left
ventricular hypertrophy
E. Gerdts1, R. Izzo2, C. Mancusi3, M.A. Losi3, M. Manzi2, G. Canciello2, N. De
Luca2, B. Trimarco3, G. De Simone2. 1University of Bergen, Department of
Clinical Science, Bergen, Norway; 2Federico II University Hospital, Department
of Translational Medical Sciences, Naples, Italy; 3Federico II University Hospital,
Department of Advanced Biomedical Sciences, Naples, Italy
Background: The notion that women have better cardiovascular (CV) outcome
than men is consolidated by strong evidence. However whether or not this sex-
specific protection persists also in the presence of hypertensive target organ dam-
age such as left ventricular (LV) hypertrophy (LVH) is unclear.
Purpose: Our objective was to assess whether the presence of LVH alters the
outcome difference between men and women with treated arterial hypertension.
Methods: Clinical, echocardiographic and outcome data from 5,395 women and
6,937 men free from prevalent CV disease from the prospective Campania Salute
Network registry were used. Median follow-up was 49 months. LVH was iden-
tified from prognostically validated sex-specific cut-off values of LV mass index
(47 g/m2.7 for women and 50 g/m2.7 for men). The impact of sex on incident ma-
jor cardiovascular events (MACE; combined acute coronary syndromes, stroke,
hospitalization for heart failure and incident atrial fibrillation) was assessed in the
presence or absence of LVH, using Cox regression analysis and reported as haz-
ard rates (HR) and 95% confidence intervals (CI).
Results: Women were older, more obese, had higher systolic blood pressure
(BP), total and high density lipoprotein cholesterol, and lower diastolic BP, serum
triglycerides and glomerular filtration rate compared to men (all p<0.01), while
the prevalence of smoking did not differ. LVH was more prevalent in women than
men (43.2 vs. 32.4%, p<0.001). Incident MACE occurred in 3.5% of men and
2.8% of women during follow-up (p=0.040). In Cox regression analysis among
subjects without LVH, adjusting for baseline differences in CV risk factors, women
without LVH had a 32% lower HR for MACE (95% CI 0.49–0.95), p=0.025) than
men without LVH (Figure, Panel A). Running the same model in subjects with
LVH, women with LVH did not have a significantly lower HR for MACE (HR 0.79
[0.59–1.06], p=0.110) than men with LVH (Figure Panel B).
Conclusions: In hypertension, presence of LVH attenuates the sex difference in
CV risk.
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Implantable cardioverter/defibrillators for primary prevention in dilated
cardiomyopathy post-DANISH: an updated meta-analysis and
systematic review of randomized controlled trials
G. Wolff1, Y. Lin1, A. Karathanos1, M. Brockmeyer1, S. Wolters1, B. Nowak2,
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Background: Sudden cardiac death (SCD) is frequent in patients with heart fail-
ure due to dilated cardiomyopathy (DCM). Implantable cardioverter/defibrillator
(ICD) device therapy is currently used for primary prevention. However, publica-
tion of the DANISH trial has recently given reason for doubt, showing no signifi-
cant improvement in all-cause mortality in comparison to contemporary medical
therapy (MT).
Purpose and methods: To reassess the value of ICD therapy in this setting,
we performed a meta-analysis of all randomized controlled trials comparing ICD
therapy to MT for primary prevention in DCM. The primary outcome was all-cause
mortality, secondary analyses were performed on sudden cardiac death, cardio-
vascular death and non-cardiac death.
Results: Five trials including a total of 2,992 patients were included in the pooled
meta-analysis. Compared to medical treatment there was a significant mortality
reduction with ICD device therapy (odds ratio (OR) 0.77, confidence interval (CI)
0.64–0.93; p=0.006). SCD was also decreased significantly (OR 0.43, CI 0.27–
0.69; p=0.0004), while cardiovascular death and non-cardiac death showed no
differences. Sensitivity analyses showed no influence of amiodarone therapy on
overall results. Analysis of MT details revealed the DANISH population to adhere
most to current guideline recommendations. In addition, it was the only study
including a substantial amount of CRT devices (56%).
Conclusions: Our meta-analysis of all available randomized evidence shows a
survival benefit of ICD therapy for primary prevention in DCM, although DANISH
results suggest an attenuation of this ICD advantage when compared to con-
temporary medical and cardiac resynchronization therapy. Until larger trials have
confirmed this finding, ICD therapy should remain the recommendation for pri-
mary prevention of SCD in DCM.
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ICDs and CRTs in patients with chronic kidney disease: a meta-
analysis
M. Shurrab1, Y. Zayed1, D. Ko2, S. Navaneethan3, N. Yadak1, A. Yaseen1,
W. Qamhia1, A. Kaoutskaia2, D. Lee4, D. Newman2, Z. Hamdan1, S. Haj-
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Background: The efficacy of implantable cardioverter defibrillators (ICDs) and
cardiac resynchronization therapy (CRT) in patients with chronic kidney disease
(CKD) remains controversial despite active use.
Purpose: The aim of this meta-analysis is to explore the association between
ICD/CRT and survival in CKD patients.
Methods: An electronic search was conducted. We included studies that reported
outcomes in CKD patients stratified by the presence of ICD, CRT or none (control
group). The primary outcome was all cause mortality. Outcomes were pooled
using random effects model. Odds ratios (OR) were reported for dichotomous
variables.
Results: 10 studies (9 retrospective and 1 prospective non-randomized) including
20920 adult patients were identified. ICD was present in 3568 patients and CRT
in 10838 patients. Baseline characteristics were similar between ICD, CRT and
control groups. Follow up ranged between 1–3 years. All cause mortality was
lower in the ICD group in comparison to control group (51% vs. 66%, OR 0.48
(95% confidence interval [CI] 0.42; 0.55), P<0.001). All cause mortality was lower
in CRT vs. ICD groups (37% vs. 42%, OR 1.38 (95% CI 1.08; 1.76), P=0.01).
No significant heterogeneity was noted for the comparisons (I2=0%, P=0.51 and
I2=31%, P=0.23, respectively).
All cause mortality
Conclusions: Concomitant use of ICDs is associated with greater survival in
observational studies of CKD patients. CRTs use showed even a better survival
in CKD patients in comparison to ICDs. A randomized controlled trial is required
to define the role of ICDs/CRTs in CKD patients.
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Implantation of ICD and CRT-D in the elderly population: will it be a
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I. Aguiar-Ricardo, N. Cortez-Dias, P. Marques, A. Magalhaes, I. Goncalves,
J. Agostinho, G. Lima Da Silva, T. Guimaraes, I. Santos, A.R. Francisco,
A. Bernardes, H.C. Costa, L. Carpinteiro, J. Fauto Pinto, J. De Sousa. Hos-
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Introduction: Implantable cardioverter defibrillator (ICD) and cardiac resynchro-
nization (CRT-D) implantation in elderly patients is effective in preventing sudden
death, although limited by the natural shorter life expectancy. The different device
brands present very variable survival estimates and it has been discussed the
availability of less expensive, less longevity generators for the elderly population.
Purpose: To determine if the expected survival rate in the elderly patient popu-
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Methods: A retrospective single-center study of consecutive patients who under-
went implantation of ICD or CRT-D after November 1995. The mean survival of
patients undergoing 1st implant or generator replacement at an advanced age
(≥75 years) was evaluated and compared to the effective longevity of the gener-
ators. Cumulative survival analyzes using the Kaplan Meier method were used.
Results: A total of 1312 cardiac devices were implanted, of which 163 generators
in elderly patients (53% CDI and 47% CRT-D). Of these, 77% corresponded to the
1st implant.
The median survival after implantation of the elderly patients was 6.8 years, not
differing according to the type of device (Log-rank P = NS). The median longevity
of CDI generators was 6.9 years, in line with the expected survival of elderly
patients. Conversely, the median CRT-D longevity was 5.8 years, lower than the
average survival of the elderly. For this reason, 21% of these CRT-D carriers were
subsequently subjected to generator replacement, due to battery exhaustion.
Conclusion: The effective longevity of ICDs is in agreement with an expected
survival of elderly patients, for which it will not make sense to provide generators
of shortened longevity for this population. The effective longevity of the CRTs
is lower than the survival expectancy of the treatments, so that, paradoxically,
generators with increased longevity should be favored.
LONG-TERM OUTCOME OF CORONARY STENTS AND
SCAFFOLDS
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Four-year clinical outcome following randomised use of
zotarolimus-eluting stents versus everolimus-eluting stents in
all-comers: insights from the DUTCH PEERS trial
M. Lowik1, L.C. Van Der Heijden1, M.M. Kok1, P. Zocca1, P.W. Danse2,
G.A.J. Jessurun3, R.W.M. Hautvast4, M. Hartmann1, M.G. Stoel1,
G.C.M. Linssen5, C.J.M. Doggen6, C. Von Birgelen1. 1Medical Spectrum Twente,
Thoraxcentrum Twente CRE, Enschede, Netherlands; 2Rijnstate Hospital, Arn-
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Background: The DUTCH PEERS (TWENTE II) trial (clinicaltrials.gov
NCT01331707) is a randomised, multicenter, single-blinded, investigator initiated
all-comers trial. All coronary syndromes were permitted with no limit for lesion
length, reference size, or number of lesions or diseased vessels to be treated. In
total, 1811 patients were 1:1 randomised to cobalt chromium-based zotarolimus-
eluting stents (ZES) versus platinum chromium-based everolimus-eluting stents
(EES). These durable polymer-based drug-eluting stents (DES) were developed
to facilitate device deliverability and to improve stent apposition to the vessel wall.
Purpose: We assessed the 4-year clinical outcome of the DUTCH PEERS trial
in terms of safety and efficacy.
Methods: Clinical outcome was assessed by means of follow-up data of the trial
participants. The primary endpoint target vessel failure (TVF) is a composite of
cardiac death, target vessel-related myocardial infarction (MI) or target vessel
revascularization. Secondary endpoints included the individual components of the
TVF and the incidence of definite-or-probable stent thrombosis. Endpoints were
analyzed by the logrank test by comparing the time to the endpoint, using the
Kaplan-Meier method. Independent contract research organizations performed
the study monitoring and clinical event adjudication.
Results: The 4-year clinical follow-up data were available in 1802 patients
(99.5%; 4 patients were lost to follow-up and 5 withdrew consent). The ZES
and EES groups showed favourable outcomes with a similar incidence of TVF
(12.1% vs. 12.1%; Logrank p=0.95). The rates of the individual components of
TVF were also similar for both stent arms: cardiac death (3.9% vs. 3.7%; Logrank
p=0.78); target vessel-related MI (3.2% vs. 2.5%; Logrank p=0.38); and target
vessel revascularization (6.8% vs. 7.5%; Logrank p=0.55), respectively. In addi-
tion, the incidence of definite-or-probable stent thrombosis was similar for patients
treated with ZES versus EES (1.5% vs. 1.2%; Logrank p=0.67).
Conclusion: At 4-year follow-up, ZES and EES showed similar and sustained
results in terms of safety and efficacy for treating all-comer patients.
Acknowledgement/Funding: This investigator-initiated study was equally sup-
ported by Boston Scientific and Medtronic
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Long term outcomes of first and second generation drug-eluting
stents in patients with diabetes: a pooled analysis of individual patient
data from SORT OUT III, IV and V trials
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Background: Diabetes is associated with increased risk of target lesion failure
after percutaneous coronary intervention (PCI). Comparisons of different drug-
eluting stent (DES) types suggested possible differences in outcomes among di-
abetic patients.
Purpose: To compare 5-year risk of target lesion failure and definite stent throm-
bosis in patients with diabetes treated with first and second generation DES.
Methods: We pooled individual patient-level data from 3 randomized SORT OUT
trials (SORT OUT III, IV and V). Target lesion failure was a composite of car-
diac death, target lesion revascularization, or definite stent thrombosis. Definite
stent thrombosis was defined according to the Academic Research Consortium
definition and evaluated up to 5 years.
Results: Out of 1,091 patients with diabetes (14.5% of patients from the 3
SORT OUT trials) included in the present analysis, 548 received sirolimus-eluting
Cypher (SES), 169 zotarolimus-eluting Endeavor (ZES-E), 184 biolimus-eluting
Nobori (BES) and 190 everolimus-eluting (EES) Xience/Promus stents.
The 5-year target lesion failure proportion in diabetic patients was: SES 19.1%,
ZES-E 25.0%, BES 16.7% and EES 11.5%. Compared to the first generation
SES, neither the ZES-E [RR=1.31, 95% Confidence Interval (CI) 0.94–1.82] nor
the biodegradable polymer BES [RR=0.87, 95% CI 0.59–1.28] were associated
with a reduced target lesion failure rate, whereas EES [RR=0.60, 95% CI 0.38–
0.96] improved the risk of target lesion failure compared to the first generation
SES.
Overall the number of definite stent thrombosis within 5-year differed significantly
between the 4 DES with the highest rate in the bioresorbable polymer BES and
zero in the EES treated patients (first generation SES 2.0%, ZES-E 2.4%, BES
3.8%, and EES 0%; p=0.04, Fisher’s Exact Test). Neither definite stent thrombosis
within 1 year (first generation SES 0.9%, ZES-E 1.8%, BES 2.2%, and EES 0%;
p=0.12, Fisher’s Exact Test) nor very late definite stent thrombosis (SES 1.1%,
ZES-E 0.6%, BES 1.7%, and EES 0%; p=0.36, Fisher’s Exact Test) differed sig-
nificantly between the stent types.
Conclusion: In diabetic patients, the EES was the only second generation drug-
eluting stent which was associated with a lower risk of target lesion failure and
definite stent thrombosis compared to the first generation SES.
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Sex-related differences in patients undergoing complex coronary
interventions in the era of 2nd generation DES
B. Vogel, J. Chandrasekhar, S. Farhan, S. Sartori, G. Giustino, C. Snyder,
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Background: The impact of sex on clinical outcomes in patients undergoing
complex coronary interventions with 2nd generation drug eluting stents (DES)
remains uncertain.
Purpose: To evaluate sex-related differences in clinical outcomes of patients
stratified by complexity of PCI.
Methods: We analysed 14,917 consecutive patients enrolled in a single-center
PCI registry between 2012 and 2015. Only patients receiving 2nd generation
drug-eluting stents (DES) were considered and categorised into complex and
non-complex PCI groups. Complex PCI was defined as the composite of ≥3
stents, <3.0 mm minimum stent diameter, severely calcified target lesion, chronic
total occlusion, or saphenous vein bypass graft as target vessel. The primary end-
point was major adverse cardiac events (MACE) defined as a composite of death,
myocardial infarction (MI) or target vessel revascularisation (TVR) at 1 year.
Results: Of the total cohort, 31.6% (n=2,005) of the non-complex PCI patients
and 30.3% (n=2,598) of the complex PCI patients were women. Compared with
men, women were older, more likely non-white with higher prevalence of diabetes
and prior cerebrovascular disease but lower prevalence of smoking and prior MI
irrespective of PCI complexity. In the non-complex PCI group women and men
had similar MACE rates (5.5% vs. 5.3%; p=0.72), whereas in patients undergoing
complex PCI women had significantly increased MACE rates (8.8% vs. 7.6%;
p=0.022). Adjusted risks, however, were similar in women and men in both groups
without evidence of interaction by sex and PCI complexity (Figure).
Adjusted risks associated with sex
Conclusion: In this analysis of patients treated with 2nd generation DES, sex did
not modify risk for MACE associated with PCI complexity, underlining the efficacy
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